June 22, 2021 -- PerkinElmer has entered into an agreement to acquire Sirion Biotech, a provider of viral vector-based technology for cell and gene therapies. The acquisition is expected to close during the third quarter of 2021.
Sirion is headquartered in Munich and has approximately 50 employees based in Germany, the U.S., and France. The company has established over a dozen licensing agreements with major pharmaceutical and biotech companies addressing more than 25 diseases and conditions.
Sirion's viral vector offerings will complement PerkinElmer's Horizon Discovery portfolio, which includes gene editing and modulation tools for CRISPR, CRISPR interference, and RNA interference (RNAi), custom cell lines, and base editing technologies. The acquisition will also further broaden PerkinElmer's existing cell and gene research solutions, including in vivo and cell painting screening technologies, immunoassays, and cell plate readers, as well as automation, microfluidics, informatics, and analytical platforms.
"By combining Sirion's innovative 'payload' transport technology with our existing Horizon genetic material editing tools and phenotypic research solutions, we will be able to support organizations' cell and gene therapy workflows as they look to streamline and accelerate their efforts," commented Prahlad Singh, PhD, president and CEO of PerkinElmer.
Financial details of the acquisition were not disclosed.
Copyright © 2021 scienceboard.net